Chronic myeloid leukemia (CML) is a malignant haemopoietic stem cell disorder which results in excessive production of cells of the myeloid series. It is associated with a consistent molecular abnormality, the BCR/ABL fusion gene. The product of BCR/ABL is a p210 protein tyrosine kinase but it is not known how this dictates the biological features of the disease. This review considers several key processes that can be suggested as candidate targets for the action of p210.
机构:
CORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USACORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USA
WOLF, DJ
SILVER, RT
论文数: 0引用数: 0
h-index: 0
机构:
CORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USACORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USA
SILVER, RT
COLEMAN, M
论文数: 0引用数: 0
h-index: 0
机构:
CORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USACORNELL UNIV, NEW YORK HOSP,MED CTR,DEPT MED,DIV HEMATOL ONCOL, ONCOL SERV, NEW YORK, NY 10021 USA